Why BioMarin FDA Panel is Positive for Sarepta (SRPT) - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Needham & Company Remains Confident in Sarepta Therapeutic (SRPT) Approval
November 25, 2015 12:09 PM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $55 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they remain confident in Eteplirsen approval following Drisapersen's AdCom.
Messer commented, "As expected, most of the discussion yesterday was around inconsistencies in the drisapersen... More
Sarepta (SRPT) PT Raised at Jefferies as BioMarin AdCom Viewed as a Positive But Remains Cautious
November 25, 2015 7:27 AM ESTJefferies analyst Gena Wang views the negative AdCom outcome for BMRN's drisapersen as a positive for Sarepta Therapeutic (NASDAQ: SRPT), although questions remain. As such the firm raised its price target to $38.00 (from $28.00) but maintained a Hold rating.
Wang commented, "We view negative... More
Sarepta Therapeutics (SRPT) on Watch as BioMarin's (BMRN) Kyndrisa Adcom Set to Kickoff
November 24, 2015 7:46 AM ESTSarepta Therapeutics (NASDAQ: SRPT) was on watch Tuesday morning ahead of competitor BioMarin's (Nasdaq: BMRN) Kyndrisa FDA committee review. The advisory meeting runs from 8:00 a.m. to 5:30 p.m. EST.
... MoreFDA Briefing Docs Offer Positives and Negatives for Sarepta (SRPT) - Baird
November 23, 2015 6:55 AM ESTBaird analyst, Brian Skorney, published a note this morning highlighting his interpretation of the FDA Briefing Documents on BioMarin's (NASDAQ: BMRN) drisapersen filed Friday. He still believes that Sarepta (NASDAQ: SRPT) has only a 35% chance of getting approval for eteplirsen... More
